| |
Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.
Kim B, Roenicke R, Roeder PM, Steinberg I, Patamawenu A, Harrison M, Van't Veer F, Koory E, Xie J, Shofner T, Matsuda K, Wettstein E, Ober E, Cooney C, Kim T, Webber JD, Meeks T, Burdette T, Clark SG, Vostal AC, Hostal A, Cohen JI, Gagne M, Ziff Z, Richard K, Burnett MR, Maule E, Callier V, Liang J, Kovacikova G, Souter SC, Weiner JA, Douek D, Ackerman ME, Wright PF, Johnson RF, Connors M
bioRxiv. 2026 Feb 5; pii: 2026.02.04.703921. doi: 10.64898/2026.02.04.703921. Epub 2026 Feb 5.
PMID: 42051288 Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.
Kim B, Roenicke R, Roeder PM, Steinberg I, Patamawenu A, Harrison M, Veer FV, Koory E, Xie J, Shofner T, Matsuda K, Wettstein E, Ober E, Cooney C, Kim T, Webber JD, Meeks T, Park C, Burdette T, Georgia S, Readler JM, Vostal AC, Hostal A, Cohen JI, Gagne M, Ziff Z, Richard K, Burnett MR, Maule E, Callier V, Liang J, Kovacikova G, Souter SC, Weiner JA, Douek D, Ackerman ME, Wright PF, Johnson RF, Connors M
iScience. 2026 Apr 17;29(4):115433. doi: 10.1016/j.isci.2026.115433. Epub 2026 Mar 20.
PMID: 42006303 Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns.
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Weiner JA, Ackerman ME, Modlin JF, Sajjad OM, Arita M, Gast C, Mainou BA, Zaman K, Hoque M, Rana S, Bandyopadhyay AS, Wright PF
Clin Infect Dis. 2026 Feb 25;82(2):e352-e360. doi: 10.1093/cid/ciaf484.
PMID: 40907970 The Search for a Respiratory Syncytial Virus Vaccine.
Wright PF
NEJM Evid. 2025 Sep;4(9):EVIDe2500194. doi: 10.1056/EVIDe2500194. Epub 2025 Aug 26.
PMID: 40856553 Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial.
Mercer LD, Seña AC, Colgate ER, Crothers JW, Wright PF, Al-Ibrahim M, Tritama E, Vincent A, Mainou BA, Zhang Y, Konopka-Anstadt J, Bandyopadhyay AS, Fix A, Konz JO, Gast C
Lancet Infect Dis. 2025 Dec;25(12):1363-1376. doi: 10.1016/S1473-3099(25)00285-3. Epub 2025 Aug 13.
PMID: 40818478 Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials.
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin J, Arita M, Bandyopadhyay AS, Gast C, Saez-Llorens X, Ruttimann RW, Van Damme P, De Coster I, Wright PF
Lancet Microbe. 2025 Jun;6(6):101028. doi: 10.1016/j.lanmic.2024.101028. Epub 2025 Apr 30.
PMID: 40318674 Binding and neutralising antibodies to respiratory syncytial virus and influenza A virus in serum and bronchoalveolar lavage fluid of healthy adults in the United States: A cross-sectional study.
Raja AI, Connor RI, Ashare A, Weiner JA, Wieland-Alter WF, Godin A, Modlin JF, Ackerman ME, Brickley EB, Wright PF
Vaccine. 2025 Apr 19;53:126936. doi: 10.1016/j.vaccine.2025.126936. Epub 2025 Mar 3.
PMID: 40037127 Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2.
Connor RI, Sakharkar M, Rappazzo CG, Kaku CI, Curtis NC, Shin S, Wieland-Alter WF, Wentworth J, Mielcarz DW, Weiner JA, Ackerman ME, Walker LM, Lee J, Wright PF
Pathog Immun. 2024;9(2):1-24. doi: 10.20411/pai.v9i2.679. Epub 2024 Jun 18.
PMID: 38933606 Nasal and Pharyngeal Mucosal Immunity to Poliovirus in Children Following Routine Immunization With Inactivated Polio Vaccine in the United States.
Godin A, Connor RI, Degefu HN, Rosato PC, Wieland-Alter WF, Axelrod KS, Kovacikova G, Weiner JA, Ackerman ME, Chen EY, Arita M, Bandyopadhyay AS, Raja AI, Modlin JF, Brickley EB, Wright PF
J Infect Dis. 2024 Nov 15;230(5):e1023-e1030. doi: 10.1093/infdis/jiae264.
PMID: 38809190 SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations.
Hederman AP, Natarajan H, Heyndrickx L, Arien KK, Wiener JA, Wright PF, Bloch EM, Tobian AAR, Redd AD, Blankson JN, Rottenstreich A, Zarbiv G, Wolf D, Goetghebuer T, Marchant A, Ackerman ME
Nat Commun. 2023 Aug 24;14(1):5171. doi: 10.1038/s41467-023-40960-0. Epub 2023 Aug 24.
PMID: 37620337 View more publications on PubMed |